AA
BIO icon

Antipodean Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History

Antipodean Advisors’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-75,000
Closed -$17M – 13
2017
Q2 		$17M Buy
75,000
+3,000
+4% +$654K 9.55% 5
2017
Q1 		$14.4M Buy
72,000
+19,000
+36% +$3.66M 7.01% 8
2016
Q4 		$9.66M Buy
+53,000
New +$9.04M 3.87% 8

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Antipodean Advisors's BIO Position: Q3 2017 in Review

Antipodean Advisors sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2017, closing a stake of 75,000 shares — an estimated $17M sold.

Antipodean Advisors first reported a position in BIO in Q4 2016 and held it in 3 quarters. The position peaked at $17M in Q2 2017. 271 funds tracked by Wall St. Rank hold BIO as of Q3 2017.

  • Antipodean Advisors reported no remaining Bio-Rad Laboratories Class A position as of Q3 2017 after selling out during the quarter.
  • Antipodean Advisors sold 75,000 Bio-Rad Laboratories Class A shares in Q3 2017, an estimated $17M.
  • Antipodean Advisors first reported a position in Bio-Rad Laboratories Class A in Q4 2016 and held it in 3 quarters.
  • Antipodean Advisors's Bio-Rad Laboratories Class A position peaked at $17M in Q2 2017.
  • 271 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2017.

Based on Antipodean Advisors's 13F filing for Q3 2017, filed 14 Nov 2017.